Opinion
Video
Author(s):
Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.
Healthy diet may lower risk of grade reclassification in patients with GG1 prostate cancer
Dr. Murphy on increasing diversity in cancer clinical trials
PACE-B trial: Five-fraction SBRT noninferior to conventional radiotherapy in prostate cancer
Dr. Schwen on focal therapies for prostate cancer
Lisa F. Newcomb, PhD, on active surveillance for prostate cancer
Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer